Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694621 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL4436548 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL5459736 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL4760197 | 1.00 | SCN9A (0.49) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6689948 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6689639 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6689951 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL6848976 | 0.91 | SCN9A (0.48) | SCN9AGPR119PDE4BMMP13TACR1 | |
| SCHEMBL4710969 | 0.90 | TACR1 (0.49) | SCN9AGPR119PDE4BTACR1RORC | |
| SCHEMBL29450269 | 0.89 | STS (0.49) | SCN9AGPR119PDE4BMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313396-B1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10329283-B2 | G protein-coupled receptor kinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-07-05 | — | — | US | disclosed |
| EP-3313396-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | The Regents of The University of Michigan (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210403-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329283-B2 | G protein-coupled receptor kinase inhibitors and methods for use of the same | GRK2, GRK4, GRK3 | SCN9A 1660/4885GPR119 182/4885PDE4B 554/4885 |
| US-20180186779-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | GRK2, GRK4, GRK3 | SCN9A 1660/4885GPR119 182/4885PDE4B 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.